sBCMA、MCL-1与初治多发性骨髓瘤患者以硼替佐米为基础的化疗方案疗效的关系  

Relationship between sBCMA,MCL-1 and the efficacy of bortezomib based chemotherapy regimen of patients with newly treated multiple myeloma

作　　者：蔺旭红 吴雯 LIN Xuhong;WU Wen(Department of Hematology,Xi′an Central Hospital,Xi′an,Shaanxi 710003,China)

机构地区：[1]陕西省西安市中心医院血液科,陕西西安710003

出　　处：《检验医学与临床》2023年第17期2469-2472,共4页Laboratory Medicine and Clinic

基　　金：陕西省2021年科技计划青年项目(2021QJ-715)。

摘　　要：目的探讨初治多发性骨髓瘤(MM)患者血清B细胞成熟抗原(sBCMA)、髓样细胞白血病蛋白-1(MCL-1)与以硼替佐米为基础化疗方案疗效的关系。方法选取该院2019年1月至2022年1月收治的83例初治MM患者作为研究对象。所有患者给予以硼替佐米为基础的化疗方案,按照疗效将其分为有效组及无效组。对比两组sBCMA及MCL-1水平及各项临床资料。采用多因素Logistic回归分析初治MM患者以硼替佐米为基础的化疗方案无效的影响因素,采用受试者工作特征(ROC)曲线分析sBCMA及MCL-1预测初治MM患者以硼替佐米为基础的化疗方案治疗无效的效能。结果有效60例,无效组23例。有效组sBCMA及MCL-1水平低于无效组,差异均有统计学意义(P<0.05);有效组国际分期系统(ISS)分期Ⅲ期比例[33.33%(20/60)]低于无效组[78.26%(18/23)],差异有统计学意义(P<0.05)。多因素Logistic回归分析发现,sBCMA及MCL-1水平升高、ISS分期Ⅲ期均是初治MM患者以硼替佐米为基础的化疗方案治疗无效的危险因素(P<0.05)。sBCMA及MCL-1单独预测初治MM患者以硼替佐米为基础的化疗方案治疗无效的曲线下面积(AUC)分别为0.751(95%CI:0.711~0.820)、0.766(95%CI:0.709~0.835),2项指标联合检测的AUC为0.895(95%CI:0.811~0.978)。结论初治MM患者sBCMA、MCL-1水平及ISS分期与以硼替佐米为基础的化疗方案疗效有关,可能成为预测初治MM患者对以硼替佐米为基础化疗方案疗效的辅助指标,且2项指标联合预测效能更高。Objective To investigate the relationship between serum B-cell maturation antigen(sBCMA),myeloid cell leukemia protein-1(MCL-1)and the efficacy of bortezomib based chemotherapy regimen of patients with newly treated multiple myeloma(MM).Methods A total of 83 patients with newly treated MM admitted to this hospital from January 2019 to January 2022 were selected as research objects.All patients were treated with bortezomib based chemotherapy regimen and divided into effective group and ineffective group according to the efficacy.The sBCMA and MCL-1 levels and various clinical data were compared between the two groups.Multivariate Logistic regression analysis was used to analyze the influencing factors for ineffective bortezomib based chemotherapy regimen of patients with newly treated MM.Receiver operating characteristic(ROC)curve was used to analyze the efficacy of sBCMA and MCL-1 to predict bortezomib based chemotherapy in patients with newly treated MM.Results There were 60 csaes in the effective group and 23 cases in the ineffective group.The sBCMA and MCL-1 levels of the effective group were lower than those of the ineffective group,and the differences were statistically significant(P<0.05).The proportion of patients with international staging system(ISS)stagingⅢof the effective group was 33.33%(20/60),which was lower than 78.26%(18/23)of the ineffective group,and the difference was statistically significant(P<0.05).Through multivariate Logistic regression analysis found that the elevated sBCMA,MCL-1 levels and ISS stagingⅢwere risk factors for ineffective bortezomib based chemotherapy regimen of patients with newly treated MM(P<0.05).The area under the curve(AUC)of sBCMA and MCL-1 for predicting the response to bortezomib based chemotherapy regimen in newly treated MM patients was 0.751(95%CI:0.711-0.820)and 0.766(95%CI:0.709-0.835),respectively,and the AUC of the combined detection of the two indicators was 0.895(95%CI:0.811-0.978).Conclusion The sBCMA and MCL-1 levels and ISS staging are associated wit

关 键 词：多发性骨髓瘤 B细胞成熟抗原 髓样细胞白血病蛋白-1 硼替佐米 

分 类 号：R733.3[医药卫生—肿瘤]